News | March 31, 2026
Novo Nordisk India sets patient-centred price of Rs. 202/day for starting dose of Ozempic and Wegovy
Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively
Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo
The timing of the partnership is crucial, as Kerala’s fertility rate has dropped to approximately 1.35–1.7 children per woman, below the replacement level of 2.1
New targeted pill offers hope for adults and teens with moderate-to-severe plaque psoriasis
It promises fewer injections for vision loss patients
The company’s ACC lineup underscores a growing body of evidence backing the drug’s performance beyond controlled trials
The once-weekly treatment targets Type 2 Diabetes Mellitus (T2DM) with demonstrated efficacy and safety
The government has appointed Dr. Sanjay Tewari as Chairperson, National Dental Commission and Dr. Mousumi Goswami, Part-Time Member, National Dental Commission
The global, first-in-human, open-label trial will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of TRI-611
Subscribe To Our Newsletter & Stay Updated
